Risk-Adjusted Hazard Rates of Biochemical Recurrence for Prostate Cancer Patients after Radical Prostatectomy

European Urology

Volumn 55, Issue 2, 2009, Pages 412-421

  Walz, Jochen ^a,b   Chun, Felix K H ^c   Klein, Eric A ^d   Reuther, Alwyn ^d   Graefen, Markus ^c   Huland, Hartwig ^c   Karakiewicz, Pierre I ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b INSTITUT PAOLI CALMETTES   (France)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Annual hazard rates; Follow up; Prostate cancer; Radical prostatectomy; Risk

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; SEMINAL VESICLE;

ADULT; AGED; COHORT STUDIES; FOLLOW-UP STUDIES; GERMANY; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OHIO; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 57649156231     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.11.005     Document Type: Article

References (21)

1. Amling C.L., Blute M.L., Bergstralh E.J., Seay T.M., Slezak J., and Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 164 (2000) 101-105
2. Dwyer A.J., Prewitt J.M., Ecker J.G., and Plunkett J. Use of the hazard rate to schedule follow-up exams efficiently. An optimization approach to patient management. Med Decis Making 3 (1983) 229-244
3. Lashner B.A., Hanauer S.B., and Silverstein M.D. Optimal timing of colonoscopy to screen for cancer in ulcerative colitis. Ann Intern Med 108 (1988) 274-278
4. Dillioglugil O., Leibman B.D., Kattan M.W., Seale-Hawkins C., Wheeler T.M., and Scardino P.T. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology 50 (1997) 93-99
5. Aus G., Abbou C.C., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 48 (2005) 546-551
6. Zincke H., Oesterling J.E., Blute M.L., Bergstralh E.J., Myers R.P., and Barrett D.M. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 152 (1994) 1850-1857
7. Noldus J., Graefen M., Haese A., Henke R.P., Hammerer P., and Huland H. Stage migration in clinically localized prostate cancer. Eur Urol 38 (2000) 74-78
8. Galper S.L., Chen M.H., Catalona W.J., Roehl K.A., Richie J.P., and D'Amico A.V. Evidence to support a continued stage migration and decrease in prostate cancer specific mortality. J Urol 175 (2006) 907-912
9. Roth A.J., Rosenfeld B., Kornblith A.B., et al. The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with prostate cancer. Cancer 97 (2003) 2910-2918
10. McNeal J.E., Redwine E.A., Freiha F.S., and Stamey T.A. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 12 (1988) 897-906
11. Gleason D.F., and Mellinger G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111 (1974) 58-64
12. Partin A.W., Mangold L.A., Lamm D.M., Walsh P.C., Epstein J.I., and Pearson J.D. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58 (2001) 843-848
13. Mazumdar M., and Glassman J.R. Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. Stat Med 19 (2000) 113-132
14. Thompson I.M., Trasher J.B., Aus A., et al. Guidelines for the management of clinically localized prostate cancer: 2007 update. J Urol 177 (2007) 2106-2131
15. Albers P., Albrecht W., Algaba F., et al. Guidelines on testicular cancer. Eur Urol 48 (2005) 885-894
16. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433-439
17. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
18. Stephenson A.J. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291 (2004) 1325-1332
19. Buskirk S.J., Pisansky T.M., Schild S.E., et al. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. J Urol 176 (2006) 985-990
20. Messing E.M., Manola J., Yao J., et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7 (2006) 472-479
21. Trock B.J., Han M., Freedland S.J., et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299 (2008) 2760-2769